AbbVie
AbbVie's revenue rose 8.6% to $61.2 billion in fiscal 2025. Its operating margin was 24.6%, up from 16.2% a year earlier. Free cash flow was $17.8 billion, down 0.1%. It paid out $12.6 billion in dividends and buybacks, 71% of free cash flow.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What AbbVie does
AbbVie researches, makes and sells prescription medicines and related products worldwide. Its main areas are immunology (Skyrizi, Rinvoq and Humira, used for autoimmune diseases), neuroscience (including Vraylar, Botox Therapeutic, and migraine and Parkinson's treatments), oncology (blood cancers and other cancers), and aesthetics (Botox Cosmetic and Juvederm). It also sells eye care products and treatments for hepatitis C and digestive conditions.
AbbVie reports as a single business segment. It makes money by selling its medicines. In the United States it sells mainly to three wholesale distributors, McKesson, Cardinal Health and Cencora. No single wholesaler accounted for more than 43% of its 2025 gross revenues in the United States. Outside the United States it sells to wholesalers and distributors and to government payers. Some aesthetic products are sold directly to doctors and other licensed providers. It also markets to doctors, hospitals, managed care providers and government agencies.
AbbVie says it competes with other drug and biotech companies, and that generic and biosimilar copies of branded drugs add pressure on products without patent protection. It says Humira already faces direct biosimilar competition around the world. AbbVie became an independent public company in 2013, when Abbott Laboratories distributed AbbVie's shares to its own shareholders.
Its biggest risks, as it describes them
- Losing patent protection on major products, and the competition from generics and biosimilars that follows.
- Research and development that may not produce new products that can be sold successfully.
- Pricing pressure from governments, rebate programs, and pharmacy benefit managers that influence access to its drugs.
- Safety or effectiveness problems with its products, and product liability claims.
- Manufacturing problems, or an interruption in supplies from single-source suppliers.
Income statement
From fiscal 2016 to 2025, earnings per share fell 4.7% a year and net income 3.7% a year, as new shares raised the share count by 9% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 9.8 | 9.2 | 12.8 | 5.6 | 5.3 |
| Debt incl. finance leases | 76.0 | 63.2 | 59.3 | 66.9 | 67.0 |
| Net debt (negative means net cash) | 66.2 | 53.9 | 46.5 | 61.3 | 61.8 |
| Net debt to EBITDA | 2.5x | 2.0x | 2.2x | 3.5x | 2.7x |
| Debt to equity | 4.9x | 3.7x | 5.7x | — | — |
| Interest coverage | 7.4x | 8.1x | 5.7x | 3.2x | 5.2x |
| Current ratio | 0.8x | 1.0x | 0.9x | 0.7x | 0.7x |
| Quick ratio | 0.7x | 0.8x | 0.8x | 0.6x | 0.6x |
Cash flow
Projections
Project AbbVie's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What AbbVie says to expect
- Full year 2026: adjusted diluted EPS
AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought AbbVie shares on the open market, and 4 insiders sold $30.8 million, $9.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | Jeffrey Ryan StewartEVP, Chief Commercial Officer | Sold | 40,619 | $293.60 | $11.9 million | Form 4 |
| Aug 14, 2026 | Nicholas DonoghoeEVP, Chief Bus/strat Officer | Sold | 32,710 | $250.00 | $8.2 million | Form 4 |
| Mar 4, 2026 | David Ryan PurdueSVP, Controller | Sold | 5,230 | $233.56 | $1.2 million | Form 4 |
| Mar 2, 2026 | Perry C SiatisEVP, GC and Secretary | Sold plan | 18,668 | $234.39 | $4.4 million | Form 4 |
| Feb 25, 2026 | Perry C SiatisEVP, GC and Secretary | Sold plan | 22,381 | $230.00 | $5.1 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 6 of 9 | 7 of 9 |
| Rule of 40 | 34.2% | 35.4% | 37.7% |
| Altman Z'' | 0.46 | −0.35 | −0.34 |
| Accruals ratio | −13.1% | −10.8% | −11.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 5 of 9 | 6 of 9 | 7 of 9 |
Compare
Put AbbVie side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | |
| Johnson & Johnson | FY25 | 6.0% | — | 20.9% | 28.6% | 0.7x | 4 | Compare |
| Pfizer | FY25 | −1.6% | — | 14.5% | 7.2% | 3.2x | 6 | Compare |
| Moderna | FY25 | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 25.6 | 28.2 | 32.8 | 33.3 | 45.8 | 56.2 | 58.1 | 54.3 | 56.3 | 61.2 |
| Revenue growth | 12.2% | 10.1% | 16.1% | 1.6% | 37.7% | 22.7% | 3.3% | −6.4% | 3.7% | 8.6% |
| Gross profit | 19.8 | 21.2 | 25.0 | 25.8 | 30.4 | 38.8 | 40.6 | 33.9 | 39.4 | 43.0 |
| Research and development | 4.4 | 5.0 | 10.3 | 6.4 | 6.4 | 6.9 | 6.5 | 7.7 | 12.8 | 9.1 |
| Operating income | 9.3 | 9.5 | 6.4 | 13.0 | 11.4 | 17.9 | 18.1 | 12.8 | 9.1 | 15.1 |
| Net income | 6.0 | 5.3 | 5.7 | 7.9 | 4.6 | 11.5 | 11.8 | 4.9 | 4.3 | 4.2 |
| Diluted EPS (US$) | 3.63 | 3.30 | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 |
| Diluted shares (millions) | 1,631 | 1,603 | 1,546 | 1,484 | 1,673 | 1,777 | 1,778 | 1,773 | 1,773 | 1,773 |
| Cash flow | ||||||||||
| Cash from operations | 7.0 | 10.0 | 13.4 | 13.3 | 17.6 | 22.8 | 24.9 | 22.8 | 18.8 | 19.0 |
| Capital expenditure | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.8 | 0.7 | 0.8 | 1.0 | 1.2 |
| Free cash flow | 6.6 | 9.4 | 12.8 | 12.8 | 16.8 | 22.0 | 24.2 | 22.1 | 17.8 | 17.8 |
| Dividends paid | 3.7 | 4.1 | 5.6 | 6.4 | 7.7 | 9.3 | 10.0 | 10.5 | 11.0 | 11.7 |
| Share buybacks | 6.0 | 1.4 | 12.0 | 0.6 | 1.0 | 0.9 | 1.5 | 2.0 | 1.7 | 1.0 |
| Acquisitions | 2.5 | 0.0 | 0.0 | 0.0 | 38.3 | 0.5 | 0.3 | 0.0 | 17.5 | 0.2 |
| Stock-based compensation | 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 0.7 | 0.7 | 0.7 | 0.9 | 1.0 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 6.4 | 9.8 | 8.1 | 39.9 | 8.5 | 9.8 | 9.2 | 12.8 | 5.6 | 5.3 |
| Debt incl. finance leases | 36.8 | 37.4 | 40.3 | 67.3 | 85.0 | 76.0 | 63.2 | 59.3 | 66.9 | 67.0 |
| Total assets | 66.1 | 70.8 | 59.4 | 89.1 | 150.6 | 146.5 | 138.8 | 134.7 | 135.2 | 134.0 |
| Total liabilities | 61.5 | 65.7 | 67.8 | 97.3 | 137.5 | 131.1 | 121.5 | 124.3 | 131.8 | 137.2 |
| Shareholders' equity | 4.6 | 5.1 | −8.4 | −8.2 | 13.1 | 15.4 | 17.3 | 10.4 | 3.3 | −3.3 |
| Margins and ratios | ||||||||||
| Gross margin | 77.2% | 75.0% | 76.4% | 77.6% | 66.4% | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% |
| Operating margin | 36.4% | 33.8% | 19.5% | 39.0% | 24.8% | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% |
| Net margin | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 8.9% | 7.6% | 6.9% |
| Free cash flow margin | 25.6% | 33.4% | 39.0% | 38.4% | 36.7% | 39.1% | 41.8% | 40.6% | 31.6% | 29.1% |
| Rule of 40 (growth + FCF margin) | 37.8% | 43.5% | 55.1% | 40.0% | 74.3% | 61.8% | 45.1% | 34.2% | 35.4% | 37.7% |
| Return on capital | 22.6% | 19.4% | 22.6% | 56.5% | 20.9% | 18.6% | 20.8% | 15.5% | 15.0% | 15.7% |
| Return on equity | 138.8% | 109.1% | — | — | — | 81.0% | 72.5% | 35.2% | 62.5% | — |
| Return on assets | 10.0% | 7.8% | 8.7% | 10.6% | 3.9% | 7.8% | 8.3% | 3.6% | 3.2% | 3.1% |
| Net debt to EBITDA | 2.9x | 2.5x | 4.0x | 1.8x | 4.3x | 2.5x | 2.0x | 2.2x | 3.5x | 2.7x |